Nicholas Wohlgemuth

Nicholas Wohlgemuth

Auto-generated profile, based on publicly available information

Nicholas Wohlgemuth

W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2020 in Nature
Verified
Journal Article
Closed access
PDF file
DBDavid F. Boyd
David F. Boyd
EAE. Kaitlynn Allen
E. Kaitlynn Allen
ARAdrienne G. Randolph
Adrienne G. Randolph
XGXi-Zhi J. Guo
Xi-Zhi J. Guo
YWYunceng Weng
Yunceng Weng
PTPaul G Thomas
Paul G Thomas

1 April 2019 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
NWNicholas Wohlgemuth
Nicholas Wohlgemuth
RHRebekah Honce
Rebekah Honce
SSStacey Schultz-Cherry
Stacey Schultz-Cherry

28 April 2020 in mBio
Verified
Journal Article
Open access
PDF file
RHRebekah Honce
Rebekah Honce
EKErik Karlsson
Erik Karlsson
NWNicholas Wohlgemuth
Nicholas Wohlgemuth
LELeonardo D. Estrada
Leonardo D. Estrada
VMVictoria A. Meliopoulos
Victoria A. Meliopoulos
SSStacey Schultz-Cherry
Stacey Schultz-Cherry
Currently, 50% of the adult population worldwide is overweight or obese. In these studies, we demonstrate that obesity not only enhances the severity of influenza infection but also impacts viral diversity. The altered microenvironment associated with obesity supports a more diverse viral quasispecies and affords the emergence of potentially pathogenic variants capable of inducing greater disease severity in lean hosts. This is likely due to the impaired interferon response, which is seen in both obese mice and obesity-derived human bronchial epithelial cells, suggesting that obesity, aside from its impact on influenza virus pathogenesis, permits the stochastic accumulation of potentially pathogenic viral variants, raising concerns about its public health impact as the prevalence of obesity continues to rise.

15 September 2016 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
OHOlivia J Hall
Olivia J Hall
NLNathachit Limjunyawong
Nathachit Limjunyawong
MVMeghan S Vermillion
Meghan S Vermillion
DRDionne P Robinson
Dionne P Robinson
NWNicholas Wohlgemuth
Nicholas Wohlgemuth
SKSabra L. Klein
Sabra L. Klein
Over 100 million women use progesterone therapies worldwide. Despite having immunomodulatory and repair properties, their effects on the outcome of viral diseases outside of the reproductive tract have not been evaluated. Administration of exogenous progesterone (at concentrations that mimic the luteal phase) to progesterone-depleted adult female mice conferred protection from both lethal and sublethal influenza A virus (IAV) infection. Progesterone treatment altered the inflammatory environment of the lungs, but had no effects on viral load. Progesterone treatment promoted faster recovery by increasing TGF-β, IL-6, IL-22, numbers of regulatory Th17 cells expressing CD39, and cellular proliferation, reducing protein leakage into the airway, improving pulmonary function, and upregulating the epidermal growth factor amphiregulin (AREG) in the lungs. Administration of rAREG to progesterone-depleted females promoted pulmonary repair and improved the outcome of IAV infection. Progesterone-treatment of AREG-deficient females could not restore protection, indicating that progesterone-mediated induction of AREG caused repair in the lungs and accelerated recovery from IAV infection. Repair and production of AREG by damaged respiratory epithelial cell cultures in vitro was increased by progesterone. Our results illustrate that progesterone is a critical host factor mediating production of AREG by epithelial cells and pulmonary tissue repair following infection, which has important implications for women’s health. Worldwide, the use of hormonal contraceptives is on the rise as a primary intervention for improving women’s health outcomes through reduced maternal mortality and increased childhood survival. There are many hormone contraceptive formulations, all of which contain some form of progesterone. Although the effects of hormone contraceptives and progesterone, specifically, have been evaluated in the context of infections of the reproductive tract, the effects of progesterone at other mucosal sites, including the respiratory tract have not been systematically evaluated. We have made the novel observation that administration of progesterone to female mice depleted of progesterone confers protection against both lethal and sublethal influenza A virus infection. In particular, progesterone reduces pulmonary inflammation, improves lung function, repairs the damaged lung epithelium, and promotes faster recovery following influenza A virus infection. Progesterone causes protection against severe outcome from influenza by inducing production of the epidermal growth factor, amphiregulin, by respiratory epithelial cells. This study provides insight into a novel mechanistic role of progesterone in the lungs and illustrates that sex hormone exposure, including through the use of hormonal contraceptives, has significant health effects beyond the reproductive tract.

17 July 2018 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
MVMeghan S. Vermillion
Meghan S. Vermillion
RURebecca L. Ursin
Rebecca L. Ursin
DKDenise I. T. Kuok
Denise I. T. Kuok
LSLandon G. Vom Steeg
Landon G. Vom Steeg
NWNicholas Wohlgemuth
Nicholas Wohlgemuth
SKSabra L. Klein
Sabra L. Klein
Amphiregulin (AREG) is an epidermal growth factor that is a significant mediator of tissue repair at mucosal sites, including in the lungs during influenza A virus (IAV) infection. Previous research illustrates that males of reproductive ages experience less severe disease and recover faster than females following infection with IAV. Whether males and females differentially produce and utilize AREG for pulmonary repair after IAV infection was investigated using murine models on a C57BL/6 background and primary mouse and human epithelial cell culture systems. Following sublethal infection with 2009 H1N1 IAV, adult female mice experienced greater morbidity and pulmonary inflammation during the acute phase of infection as well as worse pulmonary function during the recovery phase of infection than males, despite having similar virus clearance kinetics. As compared with females, AREG expression was greater in the lungs of male mice as well as in primary respiratory epithelial cells derived from mouse and human male donors, in response to H1N1 IAVs. Internalization of the epidermal growth factor receptor (EGFR) was also greater in respiratory epithelial cells derived from male than female mice. IAV infection of Areg knock-out (Areg−/−) mice eliminated sex differences in IAV pathogenesis, with a more significant role for AREG in infection of male compared to female mice. Deletion of Areg had no effect on virus replication kinetics in either sex. Gonadectomy and treatment of either wild-type or Areg−/− males with testosterone improved the outcome of IAV as compared with their placebo-treated conspecifics. Taken together, these data show that elevated levels of testosterone and AREG, either independently or in combination, improve resilience (i.e., repair and recovery of damaged tissue) and contribute to better influenza outcomes in males compared with females.

14 April 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Luis Martinez-SobridoLuis Martinez-Sobrido
Luis Martinez-Sobrido
PLPilar Blanco Lobo
Pilar Blanco Lobo
LRLaura Rodriguez
Laura Rodriguez
TFTheresa Fitzgerald
Theresa Fitzgerald
HZHanyuan Zhang
Hanyuan Zhang
SSStacey Schultz-Cherry
Stacey Schultz-Cherry
The continual emergence of novel influenza A strains from non-human hosts requires constant vigilance and the need for ongoing research to identify strains that may pose a human public health risk. Since 1999, canine H3 influenza A viruses (CIVs) have caused many thousands or millions of respiratory infections in dogs in the United States. While no human infections with CIVs have been reported to date, these viruses could pose a zoonotic risk. In these studies, the National Institutes of Allergy and Infectious Diseases (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) network collaboratively demonstrated that CIVs replicated in some primary human cells and transmitted effectively in mammalian models. While people born after 1970 had little or no pre-existing humoral immunity against CIVs, the viruses were sensitive to existing antivirals and we identified a panel of H3 cross-reactive human monoclonal antibodies (hmAbs) that could have prophylactic and/or therapeutic value. Our data predict these CIVs posed a low risk to humans. Importantly, we showed that the CEIRS network could work together to provide basic research information important for characterizing emerging influenza viruses, although there were valuable lessons learned. The 2009 influenza pandemic was a stark reminder that ongoing vigilance is critical to protect the public from an influenza pandemic. The continual evolution of influenza viruses and emergence from animal reservoirs, leads to the need to quickly identify strains that pose a public health risk. In these studies, members of the National Institutes of Allergy and Infectious Diseases (NIAID) Centers for Excellence in Influenza Research and Surveillance (CEIRS) network worked together to demonstrate that the emerging canine H3 influenza viruses posed a low risk to public health and identified several therapeutic options in the event of an emergence. In addition to providing important new basic research, many lessons were learned that may be important in dealing with any emerging disease outbreak.